SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

Mannatech ($MTEX) is experiencing heightened interest following a substantial surge in trading volume, with community members aggressively speculating on a potential low-float short squeeze. Discussions are centered on its micro-cap status and the possibility of a multi-day parabolic run, drawing comparisons to other recent volatile movers, though some express caution regarding a potential pump and dump.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is trending following a proposed merger with Applied Digital's cloud computing business to create ChronoScale, an accelerated GPU compute platform for AI workloads. This strategic shift from medical hardware to the rapidly expanding AI infrastructure sector is generating significant community discussion, with many envisioning a complete valuation framework change and others cautious about the implications for existing shareholders.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is experiencing significant momentum driven by positive preliminary Phase 3 trial data, demonstrating a substantial reduction in breast cancer recurrence rates. This, coupled with an extended insider share lock-up signaling strong management confidence and extremely high short interest borrow rates, has the community actively discussing a potential short squeeze and long-term valuation prospects for this low-float biotech.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is currently in focus after Duchenne's inclusion on the U.S. newborn screening panel, which bulls argue positions its gene therapy, Elevidys, for a significant market expansion. Despite strong community support for its real-world impact and pipeline potential, investors are closely watching competitive developments, particularly positive trial data from other DMD therapies, while also assessing the company's financial strategy and upcoming data catalysts.

Global X Funds - Global X Uranium ETF

Global X Uranium ETF

The Global X Uranium ETF (URA) is trending as the exponential power demands of AI accelerate the urgent need for stable nuclear energy, positioning it as critical infrastructure. The community is actively discussing a structural uranium supply deficit, rising spot prices, and significant accumulation by investment vehicles, driving strong expectations for a major sector rally.

Solidion Technology, Inc. engages in researching, developing and manufacturing battery components and materials, batteries and related energy storage products for the automotive electric vehicle and other markets. The company was founded on June 30, 2023 and is headquartered in Dallas, TX.

Solidion Technology Inc

Solidion Technology ($STI) is trending following news of a second grant from the U.S. Department of Energy for advanced nuclear materials and its work on uninterruptible power supply systems for AI data centers. The community is actively discussing a potential short squeeze fueled by a very low share float and high borrow rates, alongside the perceived value of its advanced battery technology. Many traders are anticipating significant upside, closely watching for further developments in the company's innovative applications within critical energy sectors.

The Clorox Co. engages in the manufacture and marketing of consumer and professional products. It operates through the following business segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment consists of cleaning products, professional products and vitamins, minerals and supplements mainly marketed and sold in the United States. The Household segments consists of bags and wraps, grilling products and cat litter marketed and sold in the United States. The Lifestyle segment refers to food, natural personal care products and water-filtration products marketed and sold in the United States. The International segment covers products sold outside the United States, excluding natural personal care products. The company was founded by Edward Hughes, Charles Husband, William Hussey, Rufus Myers, and Archibald Taft on May 3, 1913 and is headquartered in Oakland, CA.

Clorox Co.

Clorox is trending due to a strong quarterly earnings beat, surpassing revenue and EPS expectations, and raising its full-year guidance. The positive news signals an accelerated recovery from its recent cyberattack, with the company rebuilding inventories and restoring distribution ahead of schedule. Community discussion highlights renewed interest in this defensive stock, with some viewing it as a turnaround play amidst broader market volatility and a potential rotation into dividend-paying assets.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

Silver (SLV) is trending amidst global supply concerns, driven by imminent export restrictions from China, set to tighten the market significantly. Recent volatility, attributed to increased margin requirements, has fueled a fierce debate, with many viewing it as a manipulated dip offering an entry point, while others caution against a "pump and dump." The community is actively discussing silver's critical role in booming industrial sectors like AI and green energy, emphasizing the growing physical supply deficit.

Didi Global, Inc. engages in the operation of mobility platforms that provides ride hailing and other related services. It operates through the following segments: China Mobility, International, and Other Initiative. The China Mobility segment consists of ride hailing, taxi hailing, chauffeur and hitch services. The International segment includes ride hailing and food delivery services in international markets, outside of China. The Other Initiatives segment mainly consists of bike and e-bike sharing, certain auto solutions, intra-city freight, community group buying, autonomous driving, and financial services. The company was founded by Wei Cheng, Qing Liu, Bo Zhang and Rui Wu on January 11, 2013 and is headquartered Beijing, China.

DiDi Global Inc - ADR

DiDi Global Inc. is trending as its major class-action lawsuit nears final resolution, fueling community anticipation for an imminent Hong Kong relisting. While some investors are debating the impact of increased international expansion costs, optimism persists regarding the company's long-term growth trajectory, particularly its aggressive advancements in autonomous driving and robotaxi technology.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco is actively discussed following a significant strategic partnership with the U.S. government and Brookfield to accelerate nuclear reactor deployment, a move seen as critical for powering future AI data centers. The community is highly bullish on Cameco's role as a leading uranium supplier amidst tightening global supply and increasing demand for nuclear energy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$PBYI I  have decided to buy a modest position.  These are the reasons:  1) growth expectations embedded in the price are very low (contrarian view), 2) the stock is actually under valued on a pure math basis, and 3) its lackluster performance puts pressure on the management and increases the chance of a sale of the company.

John

J. Voms

James McLay

Mike

James Cacciabeve

jon lang

StockTwits Web

Puma Biotechnology Inc

 I  have decided to buy a modest position.  These are the reasons:  1) growth expectations embedded in the price are very low (contrarian view), 2) the stock is actually under valued on a pure math basis, and 3) its lackluster performance puts pressure on the management and increases the chance of a sale of the company.

August Steffen

@Itinerant 10-12 a share, most likely, if phase 2 data is not very promising. With good data, we could see something 20-30 dollars a share. Won&#39;t be long, most likely before June 2026

Fred Sanford

 10-12 a share, most likely, if phase 2 data is not very promising. With good data, we could see something 20-30 dollars a share. Won't be long, most likely before June 2026